Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | AHR | P35869 | 2/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | TDP2 | O95551 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | CASP9 | P55211 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.47 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4317475 | 0.84 | CYP2A6 (0.44) | ALOX15HSD17B10AHRPDK2CYP1A2 | |
| SCHEMBL2062062 | 0.79 | NPC1 (0.52) | ALOX15HSD17B10AHRPDK2CA12 | |
| SCHEMBL25405402 | 0.78 | CLK4 (0.60) | CYP1A2TDP2ALDH1A1TYRO3NTRK2 | |
| SCHEMBL2061125 | 0.77 | PARP10 (0.53) | AHRPDK2CYP1A2TDP2CASP3 | |
| SCHEMBL2313287 | 0.77 | AHR (0.70) | AHRPDK2CYP1A2TDP2CASP3 | |
| SCHEMBL14061414 | 0.77 | CA12 (0.56) | ALOX15HSD17B10AHRPDK2CYP1A2 | |
| SCHEMBL17376995 | 0.74 | CHRNB2 (0.42) | CYP1A2TDP2 | |
| SCHEMBL30225261 | 0.74 | CHRNB2 (0.42) | CYP1A2TDP2 | |
| SCHEMBL23975908 | 0.74 | CHRNB2 (0.42) | CYP1A2TDP2 | |
| SCHEMBL7596114 | 0.74 | OR51E2 (0.48) | AHRPDK2CYP1A2TDP2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 305 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4678634-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | Haihe Biopharma Co., Ltd. (CN) | 2026-01-14 | — | — | EP | claimed |
| EP-4611899-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | Petra Pharma Corporation (US) | 2025-09-10 | — | — | EP | claimed |
| US-20240376055-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-11-14 | — | — | US | claimed |
| WO-2024183793-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | 上海海和药物研究开发股份有限公司 | 2024-09-12 | — | — | WO | claimed |
| US-20240182460-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION | 2024-06-06 | — | — | US | claimed |
| WO-2024097172-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION (US) | 2024-05-10 | — | — | WO | claimed |
| US-20180277766-A1 | THERMALLY ACTIVATED DELAYED FLUORESCENCE ORGANIC LIGHT EMITTING DIODE HAVING HOST MATRIX POLARITY CO-DOPING | DOW GLOBAL TECHNOLOGIES LLC | 2018-09-27 | — | — | US | claimed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | claimed |
| EP-1963273-A2 | SUBSTITUTED ISOQUINOLINE-1,3(2H,4H)-DIONES, 1-THIOXO-1,4-DIHYDRO-2H-ISOQUINOLINE-3-ONES AND 1,4-DIHYDRO-3(2H)-ISOQUINOLONES AND USE THEREOF AS KINASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2008-09-03 | — | — | EP | claimed |
| US-20080085890-A1 | Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof | WYETH (US) | 2008-04-10 | — | — | US | claimed |
| WO-2007075783-A2 | SUBSTITUTED ISOQUINOLINE-1,3(2H,4H)-DIONES, 1-THIOXO-1,4-DIHYDRO-2H-ISOQUINOLINE-3-ONES AND 1,4-DIHYDRO-3(2H)-ISOQUINOLONES AND USE THEREOF AS KINASE INHIBITOR | WYETH (US) | 2007-07-05 | — | — | WO | claimed |
| EP-0789577-B1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORP (US) | 2003-03-12 | — | — | EP | claimed |
| EP-0628030-B1 | 2,3,4,5-TETRAHYDRO-1H --3-BENZAZEPINES HAVING ANTI-PSYCHOTIC ACTIVITY, AND SYNTHESIS OF $g(a)-SUBSTITUTED-ARYLACETAMIDES | SCHERING CORP (US) | 2002-12-11 | — | — | EP | claimed |
| US-5530125-A | REACTING ARYLACETAMIDE WITH STRONG BASE IN INERT APROTIC SOLVENT, THEN WITH SPECIFIED REACTANT IN PRESENCE OF TRANSITION METAL CATALYST TO ADD ALPHA-SUBSTITUENT,REDUCING TO AMINE | SCHERING CORPORTION (US) | 1996-06-25 | — | — | US | claimed |
| EP-0628030-A1 | 2,3,4,5-TETRAHYDRO-1H --3-BENZAZEPINES HAVING ANTI-PSYCHOTIC ACTIVITY, AND SYNTHESIS OF $g(a)-SUBSTITUTED-ARYLACETAMIDES | SCHERING CORPORATION (US) | 1994-12-14 | — | — | EP | claimed |
| WO-1993016997-A1 | 2,3,4,5-TETRAHYDRO-1H^_-3-BENZAZEPINES HAVING ANTI-PSYCHOTIC ACTIVITY, AND SYNTHESIS OF α-SUBSTITUTED-ARYLACETAMIDES | SCHERING CORPORATION (US) | 1993-09-02 | — | — | WO | claimed |
| WO-2026107076-A1 | CDK2 INHIBITOR COMPOUNDS | ALEKSIA THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4722195-A1 | PH-SENSITIVE CATIONIC LIPID AND LIPID NANOPARTICLES | National University Corporation Hokkaido University (JP) | 2026-04-08 | — | — | EP | disclosed |
| US-3946018-A | ANTICONVULSANTS | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1976-03-23 | — | — | US | disclosed |
| US-3946018-A | ANTICONVULSANTS | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1976-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | ALOX15 1766/4885HSD17B10 3929/4885AHR 381/4885 |
| US-20240376055-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | ALOX15 1362/4885HSD17B10 1094/4885AHR 4252/4885 |
| US-20080085890-A1 | Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof | SULT1E1, RECQL, HAX1 | ALOX15 2954/4885HSD17B10 1969/4885AHR 1357/4885 |
| US-20240182460-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | ALOX15 2996/4885HSD17B10 466/4885AHR 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.